MedAvail Holdings, Inc (MDVL) Appoints Ramona Seabaugh as CFO

MedAvail Holdings, Inc. (Nasdaq: MDVL) (“MedAvail” or the “Company”), a technology-enabled pharmacy company, today announced the appointment of Ramona Seabaugh as Chief Financial Officer effective immediately. As a key member of MedAvail’s executive leadership team, Ms. Seabaugh will lead the Company’s financial operations.

“Ramona’s pharmacy industry expertise and extensive financial leadership experience will be invaluable in executing our strategy to drive operational and financial performance,” said Ed Kilroy, President and Chief Executive Officer of MedAvail. “I am pleased to welcome Ramona to our team, as we continue to expand into new geographies and transform the pharmacy experience for seniors.”

Ms. Seabaugh brings to MedAvail more than 20 years of experience with pharmacy and healthcare services organizations leading strategic growth initiatives. She most recently served as Vice President of Finance at Vixxo Corporation, a facilities management company. Prior to Vixxo, Ms. Seabaugh served as the Vice President of Finance at Ascension Pharmacy Services, a division within one of the largest non-profit health systems in the United States. Previously, she was appointed as Chief Financial Officer of Banner Pharmacy Services, a division within Banner Health. Earlier in her career, Ms. Seabaugh held various leadership positions in finance, including with Millennium Pharmacy Systems, Walgreens Company, Astellas Pharma and Caremark Rx. She holds a Bachelor of Science in Finance from the University of Wisconsin and an MBA from Lake Forest Graduate School.

“MedAvail has a unique embedded pharmacy model and a tremendous market opportunity with Medicare beneficiaries,” said Ms. Seabaugh. “I look forward to helping the team accelerate MedAvail’s growth and create additional value for MedAvail shareholders.”

You May Also Be Interested In

• IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
• WNS Holdings (WNS) Announces CFO Transition
• ImmunityBio (IBRX) Announces Positive OS Results of Anktiva Combined With Checkpoint Inhibitors in NSLC